Latuda lurasidone: Preliminary Phase III data

Preliminary data from 430 patients in the modified intent-to-treat (mITT) population of the double-blind, Asian Phase III PASTEL trial showed that once-daily 40 mg lurasidone met the primary endpoint of reducing PANSS total

Read the full 331 word article

User Sign In